Abstract
OBJECTIVE: To determine the tigecycline in-vitro susceptibility of naive gram-negative pathogens from serious infections in Delhi, India. METHODS: During July to October 2007 investigations were carried out to determine the tigecycline in vitro susceptibility of 50 consecutive gram-negative pathogens from serious infections at the Sant Parmanand Hospital, Delhi, India. Minimum tigecycline inhibitory concentrations were determined employing the E test method (AB Biodisk). RESULTS: Twenty-four percent of isolates were found to be tigecycline resistant or partly susceptible. Susceptibility of the isolates was lower than meropenem but similar to piperacillin-tazobactam, amoxicillin-clavulanic acid, and amikacin. CONCLUSION: Tigecycline resistance was prevalent in the gram-negative isolates from serious infections prior to its marketing in India. The choice of any recently marketed antibiotic for a pilot treatment against serious gram-negative infections should not be automatic. In the initial phase of its marketing, it should be evaluated in parallel with the antibiotics with excellent local susceptibility profiles.
Article Type
Research Article
First Page
1558
Last Page
1560
Recommended Citation
Arya, Subhash C. and Agarwal, Nirmala
(2008)
"Tigecycline in-vitro susceptibility and antibiotics' fitness for gram-negative pathogens,"
Saudi Medical Journal: Vol. 29:
Iss.
11, Article 4.
DOI: https://doi.org/10.15537/1658-3175.4526